"Management During Q4 FY2023 Earnings Conference Call”
Saharsh Davuluri: Yes, see, I think commercialization is happening, Sanjaya. I think I’ll also just add another
point here. See, commercialization of molecules are happening. That commercialization is
recorded as commercial revenue. That revenue on an annual level is fairly stable. At a
quarterly level, even commercial molecules can have lumpiness because some of the lowervolume CMS molecules that we do, we don’t necessarily ship out material every quarter. We
ship out maybe twice a year, 3 times a year or maybe sometimes once a year. So again, I think
Q4 by itself for CMS is not a representation of the CMS business as a base. But if you look at the overall CMS business of FY '23, it’s a good legitimate base for the business.
Considering above coent How one should try to model the revenue going forward for Neuland?
| Subscribe To Our Free Newsletter |
